• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PXS
Click for more information
0.00% 8.5¢

PHARMAXIS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PXS Appendix 3B - Exercise of Employee Options01/09/17
PXS Change in substantial holding30/08/17
PXS Pharmaxis Investor Presentation30/08/17
PXS Change in substantial holding29/08/17
PXS Boehringer Ingelheim Initiates Phase IIa Study in NASHPRICE SENSITIVE25/08/17
PXS Positive Recommendation for Broader Bronchitol Access in AusPRICE SENSITIVE18/08/17
PXS Appendix 3B - Exercise of Employee Options14/08/17
PXS Preliminary Final Report June 2017PRICE SENSITIVE11/08/17
PXS Investor Presentation01/08/17
PXS Quarterly Shareholder Update - June 201728/07/17
PXS Appendix 4C - quarterly June 2017PRICE SENSITIVE28/07/17
PXS Presentation by CEO at Bioshares Biotech Summit21/07/17
PXS Proposed Issue of Securities to Chief Executive Officer18/07/17
PXS Appendix 3B - Employee Performance Rights and Shares - 201718/07/17
PXS Pharmaxis Investor Presentation29/06/17
PXS Interview with Pharmaxis Chief Executive Officer13/06/17
PXS Pharmaxis Announces Results of Pivotal CF Clinical TrialPRICE SENSITIVE13/06/17
PXS Initial Director's Interest Notice07/06/17
PXS Director Appointment07/06/17
PXS Investor Presentation15/05/17
PXS Pharmaxis Set to Generate Further Euro 10m Milestone PaymentPRICE SENSITIVE15/05/17
PXS Pharmaxis Appoints Chiesi as Bronchitol Distributor in ItalyPRICE SENSITIVE08/05/17
PXS Appendix 4C - quarterly cash flowPRICE SENSITIVE18/04/17
PXS Quarterly Shareholder Update March 2017PRICE SENSITIVE18/04/17
PXS Change in substantial holding05/04/17
PXS Change in substantial holding04/04/17
PXS Change in substantial holding from AEF03/04/17
PXS Change in substantial holding31/03/17
PXS Change in substantial holding from AEF30/03/17
PXS Change in substantial holding from AEF13/03/17
PXS Synairgen Collaboration ProgressPRICE SENSITIVE13/03/17
PXS Pharmaxis Completes Treatment Phase in Pivotol Trial23/02/17
PXS Half Yearly Report and AccountsPRICE SENSITIVE17/02/17
PXS Updated Investor Presentation13/02/17
PXS Change in substantial holding from AEF03/02/17
PXS Quarterly Report to Shareholders - December 201630/01/17
PXS Appendix 4C - quarterlyPRICE SENSITIVE30/01/17
PXS Appendix 3B - Exercise of Employee Options25/01/17
PXS Appendix 3B - Exercise of Employee Options12/12/16
PXS Change of Director's Interest Notice07/12/16
PXS Change of Director's Interest Notice - Mr Gary Phillips30/11/16
PXS Appendix 3B - Issue of Employee Options30/11/16
PXS Results of Meeting30/11/16
PXS CEO Address to 2016 AGM29/11/16
PXS Chairman's Address to ShareholdersPRICE SENSITIVE29/11/16
PXS Investor Briefing - Presentation23/11/16
PXS Research Collaboration with Woolcock InstitutePRICE SENSITIVE15/11/16
PXS Appendix 3B - exercise of employee options-PXS.AX 31/10/16
PXS Appendix 4C - quarterly-PXS.AX PRICE SENSITIVE28/10/16
PXS Quarterly Shareholder Update - September 2016-PXS.AX 28/10/16
PXS Notice of Annual General Meeting/Proxy Form-PXS.AX 26/10/16
PXS Copy of Corporate Governance Statement-PXS.AX 26/10/16
PXS Appendix 4G - Key to Disclosures-PXS.AX 26/10/16
PXS Annual Report to shareholders-PXS.AX 26/10/16
PXS Change of Director's Interest Notice-PXS.AX 04/10/16
PXS Change in substantial holding-PXS.AX 29/09/16
PXS Appendix 3B - Exercise of Employee Options-PXS.AX 27/09/16
PXS Pharmaxis Announces Russian Approval for Bronchitol-PXS.AX PRICE SENSITIVE27/09/16
PXS Investor presentation - 6 September 2016-PXS.AX 06/09/16
PXS Preliminary Final Report-PXS.AX PRICE SENSITIVE19/08/16
PXS Change of Director's Interest Notice - M McComas-PXS.AX 15/08/16
PXS Pharmaxis Quarterly Shareholder Update - June 2016-PXS.AX 29/07/16
PXS Pharmaxis presentation at Bioshares 2016 Biotech Summit-PXS.AX 29/07/16
PXS Appendix 4C - quarterly-PXS.AX PRICE SENSITIVE29/07/16
PXS Proposed Issue of Securities to Chief Executive Officer-PXS.AX 26/07/16
PXS Appendix 3B - issue of employee options and shares-PXS.AX 26/07/16
PXS Pharmaxis Completes Recruitment of CF Clinical Trial for US-PXS.AX PRICE SENSITIVE15/07/16
PXS BIO 2016 - Shareholder Update-PXS.AX 21/06/16
PXS Investor presentation 9 June 2016-PXS.AX 09/06/16
PXS Corporate Governance Statement-PXS.AX 04/05/16
PXS Completion of Unmarketable Parcel Share Sale Facility-PXS.AX 04/05/16
PXS Appendix 4C - quarterly March 2016-PXS.AX PRICE SENSITIVE14/04/16
PXS Quarterly Shareholder Update - March 2016-PXS.AX 14/04/16
PXS Synairgen Collaboration ProgressPRICE SENSITIVE23/03/16
PXS Updated Investor Presentation14/03/16
PXS Becoming a substantial holder from AEF26/02/16
PXS Establishment of Unmarketable Parcel Sale Facility26/02/16
PXS Half Yearly Report and AccountsPRICE SENSITIVE26/02/16
PXS Quarterly Share Update - December 2015PRICE SENSITIVE29/01/16
PXS Appendix 4C - quarterlyPRICE SENSITIVE29/01/16
PXS Appendix 3B - exercise of employee options12/01/16
PXS Updated Investor Presentation12/01/16
PXS Bronchitol Paediatric CF Trial Reports Postive ResultsPRICE SENSITIVE16/12/15
PXS Investor presentation25/11/15
PXS Change of Director's Interest Notice20/11/15
PXS Appendix 3B - grant of employee options20/11/15
PXS Results of Meeting20/11/15
PXS AGM Presentation19/11/15
PXS Chairman's Address to Shareholders19/11/15
PXS Appendix 4C - quarterlyPRICE SENSITIVE23/10/15
PXS Quarterly Investor Update - September 201523/10/15
PXS Annual Report to shareholders16/10/15
PXS Notice of Annual General Meeting/Proxy Form16/10/15
PXS Investor presentation06/10/15
PXS PXS Releases Successful Phase Results of Phase 1 TrialPRICE SENSITIVE22/09/15
PXS Pharmaxis Investor Briefing - Drug Discovery22/09/15
PXS Change in substantial holding10/09/15
PXS Appendix 3B - exercise of employee options20/08/15
PXS Appendix 4G19/08/15
PXS Preliminary Final ReportPRICE SENSITIVE19/08/15
PXS Appendix 3B - Exercise of Employee Options
01/09/17
PXS Change in substantial holding
30/08/17
PXS Pharmaxis Investor Presentation
30/08/17
PXS Change in substantial holding
29/08/17
PXS Boehringer Ingelheim Initiates Phase IIa Study in NASH
25/08/17PRICE SENSITIVE
PXS Positive Recommendation for Broader Bronchitol Access in Aus
18/08/17PRICE SENSITIVE
PXS Appendix 3B - Exercise of Employee Options
14/08/17
PXS Preliminary Final Report June 2017
11/08/17PRICE SENSITIVE
PXS Investor Presentation
01/08/17
PXS Quarterly Shareholder Update - June 2017
28/07/17
PXS Appendix 4C - quarterly June 2017
28/07/17PRICE SENSITIVE
PXS Presentation by CEO at Bioshares Biotech Summit
21/07/17
PXS Proposed Issue of Securities to Chief Executive Officer
18/07/17
PXS Appendix 3B - Employee Performance Rights and Shares - 2017
18/07/17
PXS Pharmaxis Investor Presentation
29/06/17
PXS Interview with Pharmaxis Chief Executive Officer
13/06/17
PXS Pharmaxis Announces Results of Pivotal CF Clinical Trial
13/06/17PRICE SENSITIVE
PXS Initial Director's Interest Notice
07/06/17
PXS Director Appointment
07/06/17
PXS Investor Presentation
15/05/17
PXS Pharmaxis Set to Generate Further Euro 10m Milestone Payment
15/05/17PRICE SENSITIVE
PXS Pharmaxis Appoints Chiesi as Bronchitol Distributor in Italy
08/05/17PRICE SENSITIVE
PXS Appendix 4C - quarterly cash flow
18/04/17PRICE SENSITIVE
PXS Quarterly Shareholder Update March 2017
18/04/17PRICE SENSITIVE
PXS Change in substantial holding
05/04/17
PXS Change in substantial holding
04/04/17
PXS Change in substantial holding from AEF
03/04/17
PXS Change in substantial holding
31/03/17
PXS Change in substantial holding from AEF
30/03/17
PXS Change in substantial holding from AEF
13/03/17
PXS Synairgen Collaboration Progress
13/03/17PRICE SENSITIVE
PXS Pharmaxis Completes Treatment Phase in Pivotol Trial
23/02/17
PXS Half Yearly Report and Accounts
17/02/17PRICE SENSITIVE
PXS Updated Investor Presentation
13/02/17
PXS Change in substantial holding from AEF
03/02/17
PXS Quarterly Report to Shareholders - December 2016
30/01/17
PXS Appendix 4C - quarterly
30/01/17PRICE SENSITIVE
PXS Appendix 3B - Exercise of Employee Options
25/01/17
PXS Appendix 3B - Exercise of Employee Options
12/12/16
PXS Change of Director's Interest Notice
07/12/16
PXS Change of Director's Interest Notice - Mr Gary Phillips
30/11/16
PXS Appendix 3B - Issue of Employee Options
30/11/16
PXS Results of Meeting
30/11/16
PXS CEO Address to 2016 AGM
29/11/16
PXS Chairman's Address to Shareholders
29/11/16PRICE SENSITIVE
PXS Investor Briefing - Presentation
23/11/16
PXS Research Collaboration with Woolcock Institute
15/11/16PRICE SENSITIVE
PXS Appendix 3B - exercise of employee options-PXS.AX
31/10/16
PXS Appendix 4C - quarterly-PXS.AX
28/10/16PRICE SENSITIVE
PXS Quarterly Shareholder Update - September 2016-PXS.AX
28/10/16
PXS Notice of Annual General Meeting/Proxy Form-PXS.AX
26/10/16
PXS Copy of Corporate Governance Statement-PXS.AX
26/10/16
PXS Appendix 4G - Key to Disclosures-PXS.AX
26/10/16
PXS Annual Report to shareholders-PXS.AX
26/10/16
PXS Change of Director's Interest Notice-PXS.AX
04/10/16
PXS Change in substantial holding-PXS.AX
29/09/16
PXS Appendix 3B - Exercise of Employee Options-PXS.AX
27/09/16
PXS Pharmaxis Announces Russian Approval for Bronchitol-PXS.AX
27/09/16PRICE SENSITIVE
PXS Investor presentation - 6 September 2016-PXS.AX
06/09/16
PXS Preliminary Final Report-PXS.AX
19/08/16PRICE SENSITIVE
PXS Change of Director's Interest Notice - M McComas-PXS.AX
15/08/16
PXS Pharmaxis Quarterly Shareholder Update - June 2016-PXS.AX
29/07/16
PXS Pharmaxis presentation at Bioshares 2016 Biotech Summit-PXS.AX
29/07/16
PXS Appendix 4C - quarterly-PXS.AX
29/07/16PRICE SENSITIVE
PXS Proposed Issue of Securities to Chief Executive Officer-PXS.AX
26/07/16
PXS Appendix 3B - issue of employee options and shares-PXS.AX
26/07/16
PXS Pharmaxis Completes Recruitment of CF Clinical Trial for US-PXS.AX
15/07/16PRICE SENSITIVE
PXS BIO 2016 - Shareholder Update-PXS.AX
21/06/16
PXS Investor presentation 9 June 2016-PXS.AX
09/06/16
PXS Corporate Governance Statement-PXS.AX
04/05/16
PXS Completion of Unmarketable Parcel Share Sale Facility-PXS.AX
04/05/16
PXS Appendix 4C - quarterly March 2016-PXS.AX
14/04/16PRICE SENSITIVE
PXS Quarterly Shareholder Update - March 2016-PXS.AX
14/04/16
PXS Synairgen Collaboration Progress
23/03/16PRICE SENSITIVE
PXS Updated Investor Presentation
14/03/16
PXS Becoming a substantial holder from AEF
26/02/16
PXS Establishment of Unmarketable Parcel Sale Facility
26/02/16
PXS Half Yearly Report and Accounts
26/02/16PRICE SENSITIVE
PXS Quarterly Share Update - December 2015
29/01/16PRICE SENSITIVE
PXS Appendix 4C - quarterly
29/01/16PRICE SENSITIVE
PXS Appendix 3B - exercise of employee options
12/01/16
PXS Updated Investor Presentation
12/01/16
PXS Bronchitol Paediatric CF Trial Reports Postive Results
16/12/15PRICE SENSITIVE
PXS Investor presentation
25/11/15
PXS Change of Director's Interest Notice
20/11/15
PXS Appendix 3B - grant of employee options
20/11/15
PXS Results of Meeting
20/11/15
PXS AGM Presentation
19/11/15
PXS Chairman's Address to Shareholders
19/11/15
PXS Appendix 4C - quarterly
23/10/15PRICE SENSITIVE
PXS Quarterly Investor Update - September 2015
23/10/15
PXS Annual Report to shareholders
16/10/15
PXS Notice of Annual General Meeting/Proxy Form
16/10/15
PXS Investor presentation
06/10/15
PXS PXS Releases Successful Phase Results of Phase 1 Trial
22/09/15PRICE SENSITIVE
PXS Pharmaxis Investor Briefing - Drug Discovery
22/09/15
PXS Change in substantial holding
10/09/15
PXS Appendix 3B - exercise of employee options
20/08/15
PXS Appendix 4G
19/08/15
PXS Preliminary Final Report
19/08/15PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Chaos reigns markets – so let's take stock of where we're at ahead of December For many people, it feels like the world has been getting crazier each year since 2020 (or 2016.) It's likely to continue
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.